U.S. Markets closed

SPDR S&P MidCap 400 ETF (MDY)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
320.09-0.03 (-0.01%)
At close: 4:00PM EDT

320.08 -0.01 (-0.00%)
After hours: 4:33PM EDT

People also watch
IJRIWMDIAXLBXLI
Full screen
Previous Close320.12
Open320.65
Bid318.62 x 100
Ask320.20 x 100
Day's Range319.85 - 320.69
52 Week Range268.25 - 326.88
Volume518,338
Avg. Volume1,080,770
Net Assets18B
NAV315.62
PE Ratio (TTM)N/A
Yield1.15%
YTD Return5.04%
Beta (3y)0.97
Expense Ratio (net)0.25%
Inception Date1995-05-04
Trade prices are not sourced from all markets
  • ETF.com8 days ago

    Least Popular ETFs Of The Year

    It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.

  • Market Realist13 days ago

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

  • Market Realist19 days ago

    How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?

    In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.